Related references
Note: Only part of the references are listed.
Article
Oncology
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
F. La Rosee et al.
LEUKEMIA (2020)
Share Paper
